Last reviewed · How we verify
NCT05962216: ReSD
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
trial testing Brexpiprazole in Psychosis in 40 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Dr. Albert Kar-Kin Chung |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 July 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Brexpiprazole (BREXPIPRAZOLE) — full drug profile →
Conditions studied
- Psychosis — all drugs for Psychosis →
- Depression — all drugs for Depression →
Sponsor
Dr. Albert Kar-Kin Chung
Who can join
Adults 18 to 65, any sex, with Psychosis or Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression. Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia. Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms. Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism. ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05962216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Brexpiprazole
Trials testing the same drug.
- NCT05017311 — Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D) · Phase 4 · recruiting
- NCT05504486 — Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety · Phase 4 · withdrawn
- NCT05169268 — Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia · recruiting
- NCT04830215 — Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder · Phase 4 · completed
- NCT04066192 — Brexpiprazole in Alcohol Use Disorder · Phase 2 · recruiting
Other recruiting trials for Psychosis
Currently open trials in the same condition.
- NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
- NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
- NCT07196462 — Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia · NA · recruiting
- NCT07364825 — Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05962216 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Albert Kar-Kin Chung
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05962216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing